This review assessed the safety of medicinal extracts of black cohosh (Actaea racemosa). The authors' concluded that limited evidence available suggested that adverse events were rare, mild and reversible and that black cohosh, and in particular the product Remifemin, appeared to be a safe herbal medicine. The authors' recognised the limitations of the evidence and their conclusions appear justified.
Authors' objectives
To assess the safety of medicinal extracts of black cohosh (Actaea racemosa).
Searching
Seven electronic sources were searched; details of the databases, dates and search terms were given in the report. In addition, the reference lists of all located papers were checked and information was sought from the World Health Organization and national drug safety bodies. Sixteen manufacturers of black cohosh preparations were contacted for data held on file. Departmental files were also searched ((Department of Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth) and colleagues with an interest in herbal medicine were contacted. No language restrictions were imposed on the searches.
Study selection
Study designs of evaluations included in the review All data from postmarketing surveillance studies, clinical trials, case reports, spontaneous reporting programmes and Phase I studies were included in the review.
Specific interventions included in the review
Papers needed to report information relating to the safety of black cohosh. Combination products and homeopathic preparations were excluded. The majority of the included clinical studies used Remifemin (Schaper and Brummer). The doses in the clinical studies ranged from 20 to 80 drops or from 2 to 6 tablets daily (dosage in mg not stated). Where stated, the treatment lasted from 20 days to 18 months.
Participants included in the review
All types of participant appeared to be eligible. The studies included participants with menopausal problems and those taking black cohosh for a variety of menstrual conditions.
Outcomes assessed in the review
All types of adverse events appeared to be eligible for the review.
How were decisions on the relevance of primary studies made?
